TY - JOUR T1 - Derivation and validation of the subscales of the severe asthma questionnaire JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA1095 VL - 58 IS - suppl 65 SP - PA1095 AU - Rupert Jones AU - Michael Hyland AU - Lanario Joseph AU - Matthew Masoli AU - Adel Mansur AU - Andrew Menzies-Gow AU - Stephen Fowler AU - James Dodd Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA1095.abstract N2 - Background: The Severe Asthma Questionnaire (SAQ) is a health related quality of life questionnaire validated for use in severe asthma. It comprises 16 items yielding a mean SAQ Total score and an additional visual analogue scale of Global rating.Aims: To derive and validate clinically relevant subscales using exploratory factor analysis (EFA).Methods: The SAQ was completed by patients attending 6 UK severe asthma centres, along with other questionnaires and clinical data were included in the analysis. EFA using principal axis factoring and promax rotation was used to achieve best fit to data.Results: 460 patients provided data, 65% women, mean age 51 (16-83) yrs. A three factor solution achieved best fit and the 16 SAQ items formed three distinct but inter-correlated groups of items which were consistent with item content. The groups of items assessed impact of severe asthma on various life activities (My Life), emotions (My Mind) and of extra-pulmonary symptoms and side effects (My Body). The subscales showed differing associations with clinically relevant variables (lung function and mood).Conclusions: The 16 items of the SAQ can be scored as a single overall score or as subscales reflecting three different constructs that people with severe asthma use when making judgements about their lives. The subscale ‘My Life’ assesses the impact on daily and family life, ‘My Mind’ assesses the emotional impact and ‘My Body’ extrapulmonary symptoms. The MCID of the subscales is being evaluated currently.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1095.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -